Influenza Drugs: Zanamivir and Peramivir – Neuraminidase Inhibitors (Nursing)

by Rhonda Lawes, PhD, RN

My Notes
  • Required.
Save Cancel
    Learning Material 3
    • PDF
      Slides Nursing Pharmacology Antiviral Medications Influenza.pdf
    • PDF
      Reference List Pharmacology Nursing.pdf
    • PDF
      Download Lecture Overview
    Report mistake

    00:00 Okay, still looking at the Neuraminidase Inhibitors, but we're going to look at Zanamivir.

    00:06 Now it ends in "VIR", remember that's the clue about viruses.

    00:10 But look at the slide got a great picture for you there.

    00:14 I love that we've shown you what it looks like for this special unique powder inhaler.

    00:19 That's why I've got the, besides shooting out there because this one is available.

    00:24 IVPO inhalation powder.

    00:27 You can also take it as a nebulizer or an intranasal.

    00:30 So we've got a lot of options for taking it will talk about those in just a minute but here's good news for really tired students.

    00:39 Look at the common adverse effects for both of these drugs.

    00:42 Oseltamivir and you've got Zanamivir what's in common? Yeah.

    00:47 Look at these two lists.

    00:49 This most common adverse effects are the same just about all the way down, right? So you don't have to memorize these separately.

    00:57 You chunk this information together and remind yourself whether it's Tamiflu.

    01:02 And what's the generic? or it's relenza? And what's the generic? Right.

    01:08 They have the most common adverse effects that most of your patients will experience are very similar.

    01:15 Now, let's talk about the more intense side effects of the relenza.

    01:19 You see we've got that inhalation powder got the name underneath it.

    01:23 That's what it kind of looks like.

    01:24 It's a very unique unit that you used for this inhalation powder.

    01:29 But think about patients with lung risk.

    01:32 So are talking about an inhalation powder.

    01:35 It would make sense.

    01:36 It'll be easier for you to remember.

    01:38 Oh, somebody with lung problems.

    01:40 This might be a problem.

    01:42 So if they've got a potential higher risk for patients who have lung disease, so if a patient who's asthmatic think when they normally inhale things in I can be a little problematic for them.

    01:52 Now if it's a bronchodilator, that's a good thing.

    01:55 But if I taking an inhaled powder this might give us some more problems.

    01:59 So it could cause a bronchospasm or some other respiratory challenges that would cause them to have what we call a respiratory decline that just means they're breathing is becoming more labored.

    02:10 They're having problems.

    02:11 They're not oxygenating as well.

    02:14 That's what respiratory decline would be.

    02:16 So somebody with lung problems takes these inhaled powders, they might cause a bronchospasm or respiratory decline.

    02:23 Now some patients.

    02:24 It's been kind of severe like they needed to be hospitalized in order to recover from from this.

    02:29 But see here's the problem.

    02:31 We're not really sure if the effect of needing to be hospitalized was because of the virus influenza virus or using the powder inhaler, but keep in mind somebody who uses a powder inhaler.

    02:45 Hey, there's some cool things about that.

    02:47 Maybe the patient has difficulty swallowing pills yours.

    02:50 Not gonna have to be IV.

    02:52 And another cool thing this is delivering the medication right to the site of the problem.

    02:58 That's usually our preferred route because the more medication we can get right to the target, That's awesome for lots of reasons.

    03:06 I get the medication to where it's needed.

    03:09 You have less systemic side effects, but if I already have sensitive lungs, this could be problematic.

    03:15 So we spent time on this just to help you keep in mind that this is an influenza infecting F impacting the respiratory system.

    03:26 It's really cool to deliver a medication right to this part of the problem.

    03:31 However, if they have difficulties with lungs already, this might not be the best choice to deliver it with this route.

    03:38 So strongly consider another route if it's problematic for a patient to have an inhale route like this.

    03:45 Okay, let's look at peramivir, again it ends in "VIR", so we know that it goes right? right against that virus, now this is an IV one so we don't see a lot of these given, in an outpatient typesetting and patients must be greater than 6 months of age.

    04:01 We gave one dose over 30 to 60 minutes.

    04:04 So technically this could be given right in an ER.

    04:08 Now adverse effects most commonly, It's the GI effects.

    04:11 I know we're giving it IV, but they can still end up with some kind of irritable GI stuff and up with diarrhea.

    04:18 Now this is also rare that they'd have a hypersensitivity disorder, but it is a possibility.

    04:23 Again common theme with with all these antivirals that we've discussed so far.

    About the Lecture

    The lecture Influenza Drugs: Zanamivir and Peramivir – Neuraminidase Inhibitors (Nursing) by Rhonda Lawes, PhD, RN is from the course Antiviral Medications (Nursing).

    Included Quiz Questions

    1. Relenza can be administered via multiple different routes.
    2. Tamiflu can cause nausea and vomiting.
    3. Relenza can only be administered as a pill.
    4. Tamiflu has the rare adverse effect of skin reaction.
    1. Relenza drug therapy requires hospitalization for some patients.
    2. Relenza increases the risk of bronchospasm.
    3. Relenza results in fewer systemic side effects when administered via powder inhaler.
    4. The only reason Relenza increases hospitalizations is that its route is via powder inhaler.
    5. Relenza can cause a high risk for complications in clients with cardiac problems.
    1. Peramivir is administered intravenously to clients 6 months of age or older.
    2. Peramivir is administered intravenously to clients 12 years of age or older.
    3. Peramivir is administered intramuscularly to clients 18 years of age or older.
    4. Peramivir is administered orally to clients 6 years of age or older.

    Author of lecture Influenza Drugs: Zanamivir and Peramivir – Neuraminidase Inhibitors (Nursing)

     Rhonda Lawes, PhD, RN

    Rhonda Lawes, PhD, RN

    Customer reviews

    5,0 of 5 stars
    5 Stars
    4 Stars
    3 Stars
    2 Stars
    1  Star